Literature DB >> 20568989

The role of ultrastructural examination in storage diseases.

Valentina Papa1, Lucia Tarantino, Paola Preda, Lucilla Badiali De Giorgi, Marina Fanin, Elena Pegoraro, Corrado Angelini, Giovanna Cenacchi.   

Abstract

Storage diseases (SDs) are rare metabolic disorders characterized by the intra- or extralysosomal accumulation of unmetabolized compounds. Different causes determine the buildup of undigested material, resulting in typical histochemical and ultrastructural changes. Ultrastructural examination of tissue from patients with clinically suspected SDs may disclose pathognomonic alterations or suggest a differential diagnosis even in the absence of clinically evident involvement of the biopsied tissue. Accurate diagnosis of SDs requires a continuous integration of clinical, biochemical, ultrastructural, and, when available, molecular data. It is also important for the pathologist to be familiar with the morphological variability characterizing each SD, because some morphologies are often the early stages of undeveloped forms and morphologically similar diseases are easily confused. The major advantages of transmission electron microscopy (TEM) techniques are discussed, emphasizing the current role of TEM as a rapid, cost-effective, and efficient diagnostic tool.

Entities:  

Mesh:

Year:  2010        PMID: 20568989     DOI: 10.3109/01913121003780593

Source DB:  PubMed          Journal:  Ultrastruct Pathol        ISSN: 0191-3123            Impact factor:   1.094


  1 in total

1.  Neurodegenerative VPS41 variants inhibit HOPS function and mTORC1-dependent TFEB/TFE3 regulation.

Authors:  Reini E N van der Welle; Rebekah Jobling; Christian Burns; Paolo Sanza; Jan A van der Beek; Alfonso Fasano; Lan Chen; Fried J Zwartkruis; Susan Zwakenberg; Edward F Griffin; Corlinda Ten Brink; Tineke Veenendaal; Nalan Liv; Conny M A van Ravenswaaij-Arts; Henny H Lemmink; Rolph Pfundt; Susan Blaser; Carolina Sepulveda; Andres M Lozano; Grace Yoon; Teresa Santiago-Sim; Cedric S Asensio; Guy A Caldwell; Kim A Caldwell; David Chitayat; Judith Klumperman
Journal:  EMBO Mol Med       Date:  2021-04-14       Impact factor: 12.137

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.